<DOC>
	<DOCNO>NCT02605265</DOCNO>
	<brief_summary>The study evaluate addition Irinotecan neoadjuvant chemoradiation . Half participant receive capecitabine alone together neoadjuvant CRT , follow cycle XELOX , receive capecitabine irinotecan CRT , follow cycle XELIRI . All participant schedule receive surgery 6-8 week completion CRT , 5 cycle adjuvant chemotherapy XELOX .</brief_summary>
	<brief_title>Trial Capecitabine With Without Irinotecan Driven UGT1A1</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>pathological confirm adenocarcinoma clinical stage T34 and/or N+ distance anal verge le 12 cm without distance metastasis KPS &gt; =70 UGT1A1*28 6/6 6/7 without previous anticancer therapy sign inform consent pregnancy breastfeed woman serious medical illness baseline blood biochemical indicator meet follow criterion : neutrophils≥1.5×10^9/L , Hb≥90g/L , PLT≥100×10^9/L , ALT/AST ≤2.5 ULN , Cr≤ 1 ULN DPD deficiency UGT1A1*28 7/7</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Neoadjuvant Chemoradiation</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>UGT1A1</keyword>
</DOC>